XOMA Purchases Commercial Payment Rights to BLA-Review-Stage Asset

Today we announced an important transaction for XOMA.

We purchased the rights to a 0.5% commercial payment stream in a BLA-review-stage asset – faricimab – for a $6 million upfront plus potential future milestone payments.

Faricimab currently is under Priority Review by the U.S. Food and Drug Administration (FDA) for potential use in patients with neovascular or “wet” age-related macular degeneration (nAMD or wAMD) and diabetic macular edema (DME) and is under review for therapeutic use in patients with diabetic retinopathy  https://www.roche.com/media/releases/med-cor-2021-07-29b.htm. Should faricimab receive marketing approval, XOMA anticipates it will receive a stream of economic payments for 10 years following the first commercial sales in each applicable jurisdiction.

This is an exciting moment for the XOMA team!  Congratulations to all who were involved.

© 2024 XOMA Corporation.  All rights reserved.

Follow us:

Linkedin Twitter

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development.  All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development.  References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.